Levisonics has developed a point-of-care blood coagulation testing machine using a novel, non-contact technology platform called Acoustic Tweezing Thromboelastometry (ATT). This technology could improve diagnostic response time for critical care providers by up to 350% and decrease the cost of blood coagulation analysis by over 30%, allowing patients in the United States to save $2.0 billion annually. Since ATT only uses a single drop of blood (1/100th the volume required by current technologies), Levisonics’ first target customers are neonatal and pediatric hospitals, where there is an opportunity for development of newborn screening tests for coagulation abnormalities.
- 0 Comments
Submit a comment * Email address not published. Required fields marked with *